palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy
Company profile
Ticker
PTN
Exchange
Website
CEO
Carl Spana
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
INTERFILM INC
SEC CIK
Corporate docs
Subsidiaries
RhoMed Incorporated ...
IRS number
954078884
PTN stock data
Latest filings (excl ownership)
S-1
IPO registration
14 Mar 24
8-K
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
15 Feb 24
10-Q
2024 Q2
Quarterly report
14 Feb 24
8-K
Palatin Announces $10 Million Registered Direct Offering
1 Feb 24
424B5
Prospectus supplement for primary offering
1 Feb 24
8-K
Palatin Completes Sale of Vyleesi® to
20 Dec 23
8-K
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
18 Dec 23
EFFECT
Notice of effectiveness
18 Dec 23
424B3
Prospectus supplement
15 Dec 23
CORRESP
Correspondence with SEC
14 Dec 23
Transcripts
PTN
Earnings call transcript
2024 Q1
14 Nov 23
PTN
Earnings call transcript
2023 Q4
28 Sep 23
PTN
Earnings call transcript
2023 Q3
16 May 23
PTN
Earnings call transcript
2023 Q1
15 Feb 23
PTN
Earnings call transcript
2023 Q1
14 Nov 22
PTN
Earnings call transcript
2022 Q4
23 Sep 22
PTN
Earnings call transcript
2022 Q3
17 May 22
PTN
Earnings call transcript
2022 Q2
15 Feb 22
PTN
Earnings call transcript
2022 Q1
15 Nov 21
PTN
Earnings call transcript
2021 Q4
29 Sep 21
Latest ownership filings
4
ROBERT K DEVEER JR
7 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
4
STEPHEN T WILLS
8 Dec 23
4
ALAN W DUNTON
6 Dec 23
144
Notice of proposed sale of securities
6 Dec 23
144
Notice of proposed sale of securities
1 Dec 23
4
CARL SPANA
16 Aug 23
4
STEPHEN T WILLS
16 Aug 23
4
ROBERT K DEVEER JR
22 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 5.52 mm | 5.52 mm | 5.52 mm | 5.52 mm | 5.52 mm | 5.52 mm |
Cash burn (monthly) | 821.54 k | 1.31 mm | 2.04 mm | 2.48 mm | 1.97 mm | 2.15 mm |
Cash used (since last report) | 4.89 mm | 7.77 mm | 12.13 mm | 14.79 mm | 11.72 mm | 12.77 mm |
Cash remaining | 633.12 k | -2.25 mm | -6.60 mm | -9.27 mm | -6.20 mm | -7.25 mm |
Runway (months of cash) | 0.8 | -1.7 | -3.2 | -3.7 | -3.1 | -3.4 |
Institutional ownership, Q2 2023
5.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 32 |
Opened positions | 4 |
Closed positions | 7 |
Increased positions | 3 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 1.81 bn |
Total shares | 876.52 k |
Total puts | 1.00 k |
Total calls | 33.30 k |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 382.55 k | $803.36 mm |
BLK Blackrock | 246.79 k | $518.26 mm |
Geode Capital Management | 66.28 k | $139.19 mm |
STT State Street | 30.30 k | $63.62 mm |
Bridgeway Capital Management | 26.12 k | $54.86 mm |
Montis Financial | 20.96 k | $44.02 mm |
NTRS Northern Trust | 18.75 k | $39.38 mm |
Millennium Management | 17.00 k | $35.70 mm |
Citadel Advisors | 16.47 k | $34.59 mm |
CIBC Asset Management | 15.00 k | $31.51 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Deveer Robert K JR | Common Stock | Sell | Dispose S | No | No | 2.03 | 155 | 314.65 | 34,845 |
6 Mar 24 | Deveer Robert K JR | Common Stock | Sell | Dispose S | No | No | 2.02 | 460 | 929.20 | 35,000 |
6 Mar 24 | Deveer Robert K JR | Common Stock | Sell | Dispose S | No | No | 2.01 | 106 | 213.06 | 35,460 |
6 Mar 24 | Deveer Robert K JR | Common Stock | Sell | Dispose S | No | No | 2.01 | 1,808 | 3.63 k | 35,566 |
6 Mar 24 | Deveer Robert K JR | Common Stock | Sell | Dispose S | No | No | 2 | 200 | 400.00 | 37,574 |
6 Mar 24 | Deveer Robert K JR | Common Stock | Sell | Dispose S | No | No | 2.0001 | 7,286 | 14.57 k | 37,574 |
6 Mar 24 | Deveer Robert K JR | Common Stock | Sell | Dispose S | No | No | 2 | 1,685 | 3.37 k | 44,860 |
6 Dec 23 | Wills Stephen T | Common Stock | Sell | Dispose S | No | No | 2.64 | 2,191 | 5.78 k | 327,522 |
6 Dec 23 | Wills Stephen T | Common Stock | Sell | Dispose S | No | No | 2.415 | 2,807 | 6.78 k | 329,713 |
4 Dec 23 | Dunton Alan W | Common Stock | Sell | Dispose S | No | No | 2.46 | 1 | 2.46 | 45,074 |
News
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
28 Feb 24
HC Wainwright & Co. Maintains Buy on Palatin Techs, Adjusts Price Target To $17
28 Feb 24
12 Health Care Stocks Moving In Wednesday's Intraday Session
28 Feb 24
Palatin Technologies' Disappointing Data From Dry Eye Disease Study, Stock Plummets
28 Feb 24
Dow Dips 200 Points; TJX Posts Upbeat Sales
28 Feb 24
Press releases
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
28 Feb 24
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
15 Feb 24
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
9 Feb 24
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
5 Feb 24
Palatin Announces Closing of $10 Million Registered Direct Offering
1 Feb 24